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Background: Adaptive immune responses that mediate protection against Chlamydia
trachomatis (CT) remain poorly defined in humans. Animal chlamydia models have
demonstrated that CD4+ Th1 cytokine responses mediate protective immunity against
reinfection. To better understand protective immunity to CT in humans, we investigated
whether select CT-specific CD4+ Th1 and CD8+ T cell cytokine responses were
associated with protection against CT reinfection in women.
Methods: Peripheral blood mononuclear cells were collected from 135 CT-infected
women at treatment and follow-up visits and stimulated with CT antigens. CD4+ and
CD8+ T-cells expressing IFN-γ, TNF-α, and/or IL-2 were assessed using intracellular
cytokine staining and cytokine responses were compared between visits and between
women with vs. without CT reinfection at follow-up.
Results: A CD4+TNF-α response was detected in the majority (77%) of study
participants at the treatment visit, but a lower proportion had this response at follow-up
(62%). CD4+ IFN-γ and CD4+ IL-2 responses occurred less frequently at the treatment
visit (32 and 18%, respectively), but increased at follow-up (51 and 41%, respectively).
CD8+ IFN-γ and CD8+ TNF-α responses were detectedmore often at follow-up (59% for
both responses) compared to the treatment visit (30% for both responses). At follow-up,
a CD4+IFN-γ response was detected more often in women without vs. with reinfection
(60 vs. 33%, P = 0.005).
Conclusions: Our findings suggest that a CT-specific CD4+ IFN-γ response is
associated with protective immunity against CT reinfection and is thus an important
component of adaptive immunity to CT in women.
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INTRODUCTION
Chlamydia trachomatis (CT), an obligate intracellular
bacterium that infects human mucosal columnar epithelial cells,
causes the most common bacterial sexually transmitted infection
(STI) globally, with more than 131 million new CT infections
annually (1). Despite prevention and control measures, CT rates
continue to rise in the U.S. and are currently at the highest
reported rates (2). CT infection is often asymptomatic and, if
it remains untreated, can ascend to the upper genital tract and
cause inflammation, which can lead to long-term complications
such as infertility, chronic pelvic pain, and ectopic pregnancy
(3, 4). While early antibiotic treatment can clear CT infection
and reduce the risk for CT-associated complications (5), it can
also potentially hinder the development of protective immunity
(6), thereby leaving individuals vulnerable to subsequent
reinfections, which occur in up to 20% of women after treatment
of CT infection (7). Arrested immunity with early treatment has
been demonstrated in the murine chlamydia model (8), and a
few studies in humans support the arrested immunity hypothesis
(6, 9–11). One of these studies demonstrated that women
who cleared CT infection before treatment (i.e., spontaneous
resolution) were 4-fold less likely to have reinfection at follow-
up compared with those with persisting CT infection at the
time of treatment (10), suggesting early treatment hindered
adaptive immunity in some individuals thereby increasing their
reinfection risk. An increase in reinfection rates is likely a major
contributing factor in the continued rise in CT infection rates
(6). The notion that CT screening programs with early treatment
efforts are contributing to the rise in CT infection highlights
the need for a preventative CT vaccine. However, CT vaccine
efforts have been hampered in part by the lack of identification
of the key immune correlates of protection against CT in
humans.
Most of our knowledge of the immune mechanisms that
protect against chlamydial infection has come from animal
models, especially murine models of C. muridarum or CT
infection. Murine models have demonstrated that antigen-
specific CD4+ T helper type 1 (Th1) responses are crucial for
eradication of primary chlamydial infection and important in
inducing a protective memory immune response, while neither
CD8+ cells nor antibody alone are necessary for clearing primary
infection (12–15). Whether humans utilize the same immune
mechanisms as animals to eradicate CT infection and develop
protective immunity against reinfection remains to be elucidated.
In a recent small study of adolescent females looking only at
IFN-γ responses, Russell et al. reported women who remained
uninfected over follow-up displayed a greater frequency of IFN-
γ-producing CD4+ T cells but not CD8+ T cells compared
to women who had incident infection (16). In another study,
which evaluated female sex workers, CT-specific IFN-γ and IL-
13 responses were associated with a decreased incidence of CT
infection (17). Thus, there are sparse human studies evaluating
CT-specific immune responses and they have been limited by
small sample size and/or lack of consensus with respect to
what cytokine is associated with protective immunity. Also, the
previous studies have not systematically analyzed the changes
in CT-specific T cell responses (both CD4+ and CD8+) over
time, nor evaluated cell-specific immune correlates of protection
against CT reinfection in humans using a sensitive approach like
intracellular cytokine staining (ICS).
We previously used ICS to demonstrate that the majority of
CT-infected women mounted a CD4+TNF-α response before
treatment, and CD4+IFN-γ T cell responses were infrequent
and, in general, of low magnitude at that time point; we also
found heterogeneous T cell responses based on different CT
antigens used in the stimulation (18). Our current study builds
on this initial work by investigating changes in CT-specific T
cell responses from the time of treatment to follow-up to better
understand the adaptive immune response to CT infection and to
evaluate whether specific immune responses are associated with
lower rates of CT reinfection at follow-up. Thus, we sought to
identify potential immune correlates of protection against CT
reinfection.
METHODS
Study Population and Procedures
This study evaluated 135 women from the study cohort described
in our previous study (18). Briefly, females ≥16 years of
age presenting to the Jefferson County Department of Health
(JCDH) STD clinic for treatment of a recent positive screening
CT NAAT (Hologic Aptima Combo 2 [AC2]; Hologic, Inc.,
Marlborough, MA) were invited to participate in a study on
immune responses to CT infection. Exclusion criteria were
pregnancy, prior hysterectomy, co-infection with HIV, syphilis,
or gonorrhea (tested at screening), immunosuppressed, or had
received antibiotics with anti-CT activity in the prior 30 days.
Patients interested in the study provided written consent and
were enrolled.
At enrollment, participants were interviewed for
sociodemographic information and the following specimens
were collected: a vaginal swab (for a wet mount), a cervical swab
(for CT, Neisseria gonorrhoeae, and Trichomonas vaginalis
testing by AC2), and blood (for isolation of peripheral
blood mononuclear cells [PBMCs]). All participants received
azithromycin 1g orally (directly observed) and were advised to
refer all sexual partners for treatment if not already treated. All
participants were scheduled for 3- and 6-month follow-up visits,
at which time they had an interview and a cervical swab (for
CT testing) and blood (for PBMCs) were collected again. CT
NAAT (AC2) was performed at the follow-up visits to screen
for CT reinfection; a test of cure had not been done after the
treatment visit as it is not CDC recommended in non-pregnant
women after CT treatment (19) and also azithromycin is highly
efficacious for urogenital CT infection (>97% cure rate) (20).
For the current study, we evaluated all women found to have
CT reinfection to date (n = 45) and a matched group of women
without reinfection (n = 90) that were matched in a 1:2 ratio by
age, race, and follow-up duration (i.e., we evaluated the follow-up
visit [3- or 6-month visit] in which a reinfected participant had
their reinfection detected and used the same follow-up visit for
the matched participant without reinfection).
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PBMC Isolation
Ficoll gradient centrifugation was used to isolate PBMCs from
blood at the University of Alabama at Birmingham (UAB) Center
for Clinical and Translational Sciences Specimen Processing and
Analytical Nexus (18, 21). Upon isolation, cells were counted and
examined for viability. PBMCs were frozen in 1mL aliquots in
90% FBS+10%DMSO and cryopreserved in liquid nitrogen until
thawed for immunological studies.
Intracellular Cytokine Staining (ICS)
PBMCs were stimulated with CT antigens and analyzed for
cytokines as previously reported (18, 21). Briefly, 2.5 × 105
cells were incubated for 2 h at 37◦C with 5% CO2 in RPMI-
10 media (RPMI 1640 medium containing 10% human AB
serum, penicillin/streptomycin [50 U/mL], HEPES [25mM] and
L-glutamine [2mM]) in the presence of antibodies reactive to
co-stimulatory molecules CD28 and CD49d (BD Biosciences,
San Diego, CA) and antigen, followed by a 5-h incubation
in the presence of Brefeldin A and Monensin (both from BD
Biosciences, San Diego, CA). Antigens used were: recombinant
CT Pgp3 (5µg/ml; Biorbyt, San Francisco, CA), pooled CT
major outer membrane protein (MOMP) peptides (5µg/ml;
VS1 75-92, VS2 132-151, VS2 145-163, VS4 300-318, VS4 308-
324; UAB Peptide Core, Birmingham, AL), and formalin-fixed
CT elementary bodies (EBs; 4µg/ml) (pooled CT EBs from
serotypes D, F and J; obtained from Dr. Richard Morrison from
the University of Arkansas for Medical Sciences, Little Rock,
AR); Staphylococcus enterotoxin B (SEB, Toxin Technologies,
Carasota, FL) was used as the positive control. RPMI-10
supplemented with anti-CD28/CD49d antibodies, but without
antigen, was used to determine background T-cell responses.
Cells were subsequently labeled with LIVE/DEAD fluorescent
reactive dye (Life Technologies, Eugene, OR), stained with
surface antibodies reactive against surface molecules CD3
(conjugated with Pacific Blue; BD biosciences, San Diego, CA),
CD4 (conjugated with Qdot 655), and CD8 (conjugated with
Qdot 605; both from Invitrogen, Carlsbad, CA), fixed and
permeabilized (Cytofix/Cytoperm, BD Biosciences, San Diego,
CA), and intracellular cytokines stained with antibodies reactive
against IFN-γ (conjugated with Alexa 700), TNF-α (conjugated
with PE-Cy7) and IL-2 (conjugated with PE; all from BD
Biosciences, San Diego, CA). Approximately 100,000 events
were acquired on a LSRII (BD Immunocytometry Systems,
San Diego, CA) and data were analyzed using FlowJo software
(v9.8.5, TreeStar, Ashland, OR). All responses are reported after
subtracting the background responses (media with antibodies
against co-stimulatory receptors was the control). A positive
cytokine response was defined as a response with >0.05%
cytokine-producing cells and 2-fold higher than the background
(media with co-stimulatory antibodies).
Statistical Analysis
Given the design, analyses took into account the 2:1 matching of
women without reinfection to those with reinfection, resulting
in clusters of size 3. For paired qualitative cytokine response
data, the change in the proportion of women with cytokine
responses from the treatment to follow-up visits were evaluated
using an extension of McNemar’s chi-square test that addresses
clustering (22). For unpaired qualitative cytokine response data,
differences in the proportion of women with a positive cytokine
response between reinfection and no reinfection groups at
follow-up were evaluated in a logistic model using a generalized
linear mixed models (GLMMs) approach with visit as a main
effect and matched group as a random effect, which accounted
for clustering of data. For quantitative cytokine response data,
cytokine responses were log-transformed given the skewed
distribution. A mixed model approach was used that accounted
for clustering with random matched group and/or participant
effects as appropriate. Association of participant characteristics
with reinfection status were examined one at a time using
a logistic GLMM with a given characteristic as a fixed main
effect and matched group as a random effect. P-values <0.05
were considered statistically significant. Analyses were performed
with R software (i.e., Obuchowski’s test, version 3.3.3) and SAS
software (version 9.3; SAS Institute, Cary, NC).
Study Approval and Participant Consent
This study was approved by the UAB Institutional Review Board
and JCDH. All study participants provided written consent
before they were enrolled in the study.
RESULTS
Participant Characteristics
Of the 135 women evaluated (45 with reinfection at follow-up
and 90 without reinfection), the median age at enrollment was
22 years (range 16–32) and the majority were African-American
and non-Hispanic (Table 1). Seventy-eight (57.8%) women had
prior chlamydia (by self-report and/or review of medical records)
and there was a trend towards a higher reinfection frequency in
women without prior CT (P = 0.070). Sixty-six (48.9%) women
were diagnosed with other co-infections (bacterial vaginosis,
trichomoniasis, or vaginal candidiasis) and these co-infections
did not significantly differ between women with and without CT
reinfection at follow-up.
As described in the methods, non-reinfected participants were
matched in a 2:1 ratio to reinfected participants by follow-up
visit. For the 135 women, we evaluated data at 93 3-month follow-
up visits (31 visits from reinfected participants and 62 from those
without infection) and 42 6-month visits (14 from reinfected
participants and 28 from nonreinfected subjects). There was no
significant difference in frequency of reporting being sexually
active since treatment in women with vs. without reinfection at
follow-up (43 [95.5%] vs. 81 [90%]; P = 0.282), nor was there
a difference in the median number of sexual partners at follow-
up (for both groups, the median number was 1 [range 1–5]).
Reinfected women more often reported having unprotected sex
since treatment compared with women without reinfection (39
[86.7%] vs. 55 [61.1%]; P = 0.005). There was no significant
difference in frequency of reporting that the partner received CT
treatment in women with vs. without reinfection (31 [68.9%] vs.
62 [68.9%], P = 0.927), nor was there a significant difference in
frequency of a reported new partner since treatment (18 [40%]
vs. 27 [30%]; P = 0.214).
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TABLE 1 | Baseline participant characteristics, stratified by chlamydia reinfection
status at follow-up.
Characteristics Total
(n = 135)
Reinfection
(n = 45)
No reinfection
(n = 90)
Age (yr), median (range) 22 (16–32) 22 (16–32) 22 (16–29)
RACE, n (%)
African-American 133 (98.5%) 44 (97.7%) 89 (98.9%)
Caucasian 2 (1.5%) 1 (2.3%) 1 (1.1%)
ETHNICITY, n (%)
Non-Hispanic 134 (99.3%) 44 (97.7%) 90 (100%)
Hispanic 1 (0.7%) 1 (2.3%) 0 (0%)
Use of hormonal
contraception, n (%)
61 (45.2%) 25 (55.6%) 36 (40%)
Prior chlamydia, n (%) 78 (57.8%) 21 (46.7%) 57 (63.3%)
Cervicitis, n (%) 20 (14.8%) 9 (20%) 11 (12.2%)
CO-INFECTION, n (%)
Bacterial Vaginosis 41 (30.4%) 14 (31.1%) 27 (30%)
Trichomoniasis 8 (5.9%) 5 (11.1%) 3 (3.3%)
Candidiasis 17 (12.6%) 2 (4.4%) 15 (16.7%)
There was trend towards lower reinfection frequency in those with prior CT (P = 0.070),
otherwise other characteristics were not associated with reinfection status (P > 0.1).
The Th1 Cytokine Hierarchy Transitioned
From TNF-α-producing CD4+ T Cells to
IFN-γ-producing CD4+ T Cells After
CT-infected Women Were Treated
We evaluated the frequency of CT-specific CD4+ and CD8+
TNF-α, IFN-γ, and/or IL-2 responses in the stimulated
PBMCs using intracellular cytokine staining. After PBMCs were
stimulated with CT antigens (CT EBs, recombinant Pgp3, and
MOMP peptides), T cells were gated from a singlet population of
lymphocytes gate by selecting either the CD3+CD4+ population
(CD4+ T cells) or CD3+CD8+ population (CD8+ T cells), and
were subsequently selected for IFN-γ- and/or TNF-α-, and/or
IL-2- producing populations for both CD4+ and CD8+T cells
(Figure 1). In the 135 participants for whom CT-specific CD4+
and CD8+ TNF-α, IFN-γ, and IL-2 responses were evaluated at
follow-up (93 3-month visits and 42 6-month visits), we found
a significant decline in the frequency of a positive CD4+TNF-
α response from the treatment visit to the follow-up visit (77
vs. 62%, P = 0.029, Figure 2A, left panel). Stratifying these
responses into 3-month and 6-month visits yielded similar trends
(Figure 2Amiddle and right panels), though they did not achieve
significance (possibly due to smaller sample size). In contrast, we
saw a significant increase in the frequency of positive CD4+IFN-
γ (from 31.8 to 51.1%, P = 0.002) and CD4+IL-2 (from 18.5 to
41.5%, P = 0.001) responses from the treatment visit to follow-
up (cumulative), respectively (Figure 2A left panel). Similar
trends for CD4+IFN-γ responses were seen for both 3-month
(P = 0.002) and 6-month visits (P = 0.352; Figure 2A middle
and right panel). We also observed a significant increase in
the frequency of positive CD8+TNF-α (from 34.1% to 59.3, P
= 0.001) and CD8+IFN-γ (from 36.3 to 58.5%, P = 0.001)
responses from the treatment visit to follow-up, while a notable
decline was found in frequency of CD8+IL-2 responses from the
treatment visit to follow-up as seen cumulatively (P = 0.024;
Figure 2B left panel) and for 3-month (P = 0.017) (Figure 2B
middle panel) and 6-month (P = 0.385) visits (Figure 2B right
panel), respectively.
Next, we evaluated whether these changes in the differential
cytokine responses between visits were associated with one
specific CT antigen or more than one of the CT antigens. At the
treatment visit, a CD4+TNF-α response to Pgp3,MOMP, and EB,
was detected in 56, 44, and 42%, respectively (Figure 3). A similar
trend in the antigen-specific CD4+TNF-α response was seen at
follow-up (cumulative), though the frequency of these responses
was much lower (35% for Pgp3, 27% forMOMP and 38% for EB).
The CD4+IFN-γ response at follow-upwasmainly to Pgp3 (40%)
and EB (24.3%). A CD4+IL-2 response occurred most often to
EBs (33.3% at follow-up), followed by MOMP (15.6% at follow-
up, Figure 3). CD8+TNF-α responses occurred mainly to Pgp3
(45.2%) and EB (43.7%) at follow-up, whereas the CD8+IFN-γ
response at follow-up was primarily against MOMP (occurring
in 43% of women; Figure 3). The variability in the frequency
of cytokine responses to different CT antigens highlights the
heterogeneity of the CT antigens contributing to the adaptive
immune response against CT.
A Significant Increase in the Magnitude of
CD4+ and CD8+ IFN-γ and TNF-α
Responses at Follow-Up Was Observed
To evaluate the change in magnitude of T cell responses at the
treatment visit and at follow-up, we measured the proportion of
cytokine-producing CT-specific T cells in PBMCs from treatment
and follow-up visits (cumulative) upon stimulation with the same
3 CT antigens. Although there was a decline in the frequency
of a positive CD4+TNF-α response at follow-up, we observed
a significant increase in the magnitude of the CD4+TNF-α
response from treatment to follow-up in participants who had a
positive response at both visits (P < 0.001 for Pgp3, MOMP, and
EB, Figure 4A). Similarly, there was an increase in the magnitude
of the CD8+TNF-α response at follow-up (P < 0.001 for Pgp3,
MOMP, and EB, Figure 4B). We also observed a significant
increase in the magnitude of CD4+IFN-γ and CD8+ IFN-γ
responses at follow-up (P < 0.001 for Pgp3, MOMP, and EB
for both CD4+ and CD8+ responses), while the magnitude of
the IL-2 response remained mostly unchanged between visits
(Figures 4A, B). Overall, there was a stronger magnitude of IFN-
γ- and TNF-α-producing T cell responses at follow-up after
therapy.
A CD4+IFN-γ Response at Follow-Up Was
Detected More Often in Women Without
Reinfection Compared to Those With
Reinfection
To determine whether a specific adaptive T cell cytokine
response was associated with protection against CT reinfection,
we compared detection of T cell cytokine responses at follow-
up in women with vs. without CT reinfection. We first analyzed
the percentage of participants whose stimulated PBMCsmounted
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FIGURE 1 | Gating strategy: Gating strategy used to analyze the quantitative and qualitative T cell cytokine responses at both treatment and follow-up visits after a
7-h PBMC stimulation with Chlamydia trachomatis (CT) antigens (Pgp3, MOMP and EB) by intracellular cytokine staining with flow cytometry. Expanded lymphocytes
were first selected based upon forward (FSC) and side scatters (SSC) before gating for a singlet population of live cells. Then they were either selected for CD4+ T
cells (CD3+CD4+) or CD8+ T cells (CD3+CD8+) before analyzing cytokine production for IFN-γ, TNF-α and IL-2 using a similar gating strategy.
CD4+ and CD8+ cytokine responses (IFN-γ, TNF-α and IL-
2) to any of the CT antigens at follow-up and the relationship
to reinfection status. A CD4+IFN-γ response was detected
more often in women without reinfection compared to those
with reinfection when analyzed cumulatively (60 vs. 33%,
P = 0.005; OR = 3.00 [95% CI: 1.40, 6.42]; Figures 5A left
panel). Upon stratifying these responses for 3-month and 6-
months follow-up visits, we found that the association remained
significant at the 3-month visit (P = 0.008), but not the 6-
month visit (P = 0.289). There was no significant association
of other CD4+ cytokine responses with reinfection status
(Figure 5A), nor was there an association of a CD8+ cytokine
response with reinfection status (Figure 5B). Since women
from the reinfected group more often reported unprotected
sex after treatment than women from the group without
reinfection (P = 0.005), we performed a multivariate analysis
(on cumulative data) examining the relationship between
CD4+IFN-γ response and reinfection status that controlled
for unprotected sex. Our analysis revealed that women with a
positive CD4+IFN-γ response had significantly lower odds of
reinfection (P = 0.002; OR=0.28; [95% CI: 0.12, 0.62]) than
those with a negative CD4+IFN-γ response after controlling
for unprotected sex in the analysis. In a subanalysis, we also
analyzed whether a CD4+IFN-γ response at the initial treatment
visit was associated with subsequent reinfection at follow-up
and found no association of a CD4+IFN-γ response at the
treatment visit with subsequent reinfection (P = 0.603) either
cumulatively or for both the follow-up visits separately. This
suggests that the timing of the CD4+IFNγ response is an
important factor in providing protective immunity against CT
reinfection.
In another subanalysis investigating the frequency of
a CD4+IFN-γ response at follow-up to each of the 3
CT antigens in both participant groups, we found that
the significant association of a CD4+IFN-γ response in
women without CT reinfection was driven primarily by
CD4+IFN-γ responses to MOMP (P = 0.039) when analyzed
cumulatively (Figure 6). Upon stratification by follow-up
visit, the association remained significant for the 3-month
follow-up visit (P = 0.031), but not the 6-month follow-up visit
(P = 0.661).
To investigate whether the magnitude of the CD4+IFN-γ
response differed at the follow-up visit in women who did
vs. did not have reinfection, we evaluated the proportion of
cytokine-producing CT-specific T cells in both groups at follow-
up. Even though we had found a cumulative difference in the
frequency of a CD4+IFN-γ response at follow-up between those
who did vs. did not have reinfection, we did not observe any
significant difference in the magnitude of the CD4+ T cell IFN-
γ responses between the groups at follow-up (Figure 7). We also
did not observe any significant difference in the mean fluorescent
intensity of CD4+IFN-γ (data not shown) at follow-up time
points, suggesting these cells also do not differ significantly
in terms of amount of IFN-γ production per cell basis. This
observation in conjunction with the above-mentioned results
suggest that the timing of a CD4+IFN-γ response may be more
important than the magnitude of the response itself in providing
protection against CT reinfection.
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FIGURE 2 | Th1 cytokine hierarchy changed from TNF-α-producing to IFN-γ-producing CD4+ T cells in chlamydia-infected women after therapy: Bar graph
representing the change in the percentage of subjects with positive CD4+ (A) and CD8+ (B) cytokine-positive T cell responses from the Tx (black bars) to FU visits
(white bars) among a cumulative 135 women and further stratified in 93 women at a 3-month visit and 42 women at a 6-month visit. Standard error of mean (SEM) is
shown on the bars. The numbers on top of the bars represent the fold change in the percent positive CD4+/CD8+ cytokine positive responses from Tx to FU visit for
the respective cytokines after PBMC stimulation. An extension of McNemar’s chi-square test was used to determine statistical significance. P < 0.05 was considered
statistically significant. ***P < 0.001, **P < 0.005, and *P < 0.05.
FIGURE 3 | T cell responses against individual Chlamydia trachomatis antigens: Bar graph representing the change in the percentage of subjects with positive CD4+
(Left) and CD8+ (Right) cytokine-positive T cell responses from the Tx (black bars) to FU visits (white bars) among 135 women (cumulative). Standard error of mean
(SEM) is shown on the bars. An extension of McNemar’s chi-square test was used to determine statistical significance. P < 0.05 was considered statistically
significant. ***P < 0.001, **P < 0.005, and *P < 0.05.
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FIGURE 4 | Increased magnitude of Chlamydia trachomatis (CT)-specific T cell cytokine responses at follow-up: Box and whisker plot with 5–95% interquartile range
showing the frequency of CT-specific positive CD4+ T cell (A) and CD8+ T cell (B) responses as measured by cytokine-producing T cells after 7 h of PBMC
stimulation with either recombinant Pgp3 protein (left panels), MOMP peptides (middle panels), or EB (right panels) and subtraction of the background responses at
treatment (Tx, gray boxes) or follow up (FU, open boxes) visits in 135 women with CT infection at the Tx visit. Compared to the Tx visit, women had a stronger
magnitude of CD4+ and CD8+ TNF-α and IFN-γ T cell responses detected at FU (P < 0.001). Line within the box represents the median and the symbols above and
below the whiskers represent the outliers that are either greater than 95th or less than 5th percentile. A log transformed mixed model was used to compare Tx vs. FU.
P < 0.05 was considered statistically significant. ***P < 0.001.
In Women With a CT-specific CD4+IFN-γ
Response Detected at Follow-up, the
CD4+IFN-γ-producing T Cells
Predominantly Co-produced Either TNF-α
or IL-2
As dual cytokine-producing T cells have been shown in general
to be functionally superior over single cytokine-producing cells
(23) and correlated with protection against chlamydia in murine
models (24), we examined the CD4+ T cells from women
who had positive CD4+IFN-γ responses for their ability to co-
produce TNF-α or IL-2. Using dual gating, we determined the
proportion of women with CD4+IFN-γ-producing T cells that
were dual positive either for TNF-α or for IL-2 for both treatment
and follow-up visits. At the follow-up (cumulative) compared to
the treatment visit, we found a significantly higher percentage of
women had CD4+ T cells that co-produced IFN-γ with TNF-
α (61 to 26%, P < 0.001) and IFN-γ with IL-2 (69 to 23%,
P < 0.001; Figure 8A). The association remained significant for
the 3-month visit (P < 0.001 for both IFN-γ +TNF-α+ and
IFN-γ+IL-2+) and still trended for the 6-month visit (P= 0.067
for IFN-γ +TNF-α+ and P = 0.014 for IFN-γ +IL-2+). Upon
evaluating the relationship of these dual cytokine responses at
follow-up with reinfection status, we did not find any significant
association (Figure 8B). This suggests that although CT-specific
CD4+ T cells that co-produce IFN-γ with either TNF-α or IL-2
are a prominent component of the adaptive immune response to
CT, it is the CD4+ IFN-γ response that is essential for protective
immunity to CT reinfection.
DISCUSSION
Lack of knowledge of the immune correlates of protection
against CT in humans has hampered efforts in developing a
vaccine against this highly prevalent STI that causes substantial
morbidity in women. The murine model of CT infection
clearly supports a Th1 IFN-γ response as necessary for
eradication of primary CT infection and a correlate for protective
immunity against CT reinfection upon re-exposure (12, 13,
25). However, the limited human research to date on CT-
specific adaptive immune responses had produced contradictory
results with respect to whether Th1- vs. Th2-associated cytokine
responses predominated in human CT infection (16, 17,
26, 27), and the studies were limited by smaller samples
sizes.
Our current study builds on our earlier study in which we
used ICS to demonstrate that the majority of CT-infected women
presenting for treatment of their CT infection had a positive
CD4+TNF-α response after stimulation of their PBMCs with
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FIGURE 5 | Women with a CD4+ IFN-γ response detected at follow-up had a lower frequency of Chlamydia trachomatis (CT) reinfection: Bar graph illustrating the
percentage of women with positive CD4+ T cell (A) and CD8+ T cell (B) responses detected after their PBMCs were stimulated with any of the three CT antigens
(Pgp3, MOMP, EB), with women stratified based on their CT status at follow-up (R = reinfection, NR = no reinfection). A significantly higher proportion of women from
the NR group (white bars) had a CD4+ IFN-γ response detected than women from the R group (black bar; P = 0.005; OR 3.00 [95% CI 1.40, 6.42]) for cumulative
follow-up. Standard error of mean (SEM) is shown on the bars. An extension of McNemar’s chi-square test was used to compare R vs. NR matched groups. P < 0.05
was considered statistically significant. **P < 0.005, and *P < 0.05.
FIGURE 6 | Differential and temporal CD4+ IFN-γ T cell response with different Chlamydia trachomatis (CT) antigens. Bar graph depicting the percentage of women
with a CD4+ IFN-γ T cell response detected after their PBMCs were stimulated with any of the three CT antigens (Pgp3, MOMP, EB), with women stratified based on
their CT status at follow-up (R = reinfection, NR = no reinfection). Stimulation with different CT antigens led to differential CD4+ IFN-γ responses, with MOMP
stimulation resulting in significantly higher CD4+ IFN-γ T cell response from women in the NR group compared to women in the R group at 3-month and 6-month
follow-up visit respectively. Standard error of mean (SEM) is shown on the bars. An extension of McNemar’s chi-square test was used to compare R vs. NR matched
groups. P < 0.05 was considered statistically significant. *P < 0.05.
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FIGURE 7 | No difference in the magnitude of the CD4+ IFN-γ response
detected in women with vs. without reinfection at follow-up: Box and
whisker plot with 5–95% interquartile range showing the percentage of
Chlamydia trachomatis (CT)-specific IFN-γ-producing CD4+ T cells at
follow-up when stimulated with CT antigens: Pgp3, MOMP and EB. No
significant difference in the magnitude of the CD4+ IFN-γ response in the
reinfection (R) group (n = 45; white box) vs. the no reinfection (NR) groups (n =
90; gray box). Line within the box represents the median and the symbols
above and below the whiskers represent the outliers that are either greater
than 95th or less than 5th percentile. A log transformed mixed model was
used to compare R vs. NR matched groups. P < 0.05 was considered
statistically significant.
CT antigens (18). In this follow-up study, we investigated their
CT-specific CD4+ and CD8+ IFN-γ, TNF-α, and IL-2 responses
at follow-up after treatment and evaluated for association of a
specific cytokine response with lower risk for CT reinfection.
There was a significant increase in the frequency of CD4+
and CD8+ IFN-γ responses from treatment to follow-up and
subsequently, there was a significant decline in the frequency
of CD4+TNF-α responses. These results suggest that the early
response upon exposure to CT in humans may be a CD4+TNF-α
response, however as the adaptive immune response evolves, it
appears to be strongly driven by IFN-γ-producing CD4+ T cells
that often co-produce other Th1 cytokines. It is possible that this
transition reflects the inability of CD4+TNF-α-producing T cells
to eradicate the infection alone, which seems to be supported by
the finding that the majority of TNF-α-producing CD4+ T cells
before treatment did not co-produce IFN-γ or IL-2, whereas at
follow-up, the majority of IFN-γ-producing CD4+ T cells co-
produced either TNF-α or IL-2, a phenotype highly indicative of
functionally superior cells (23). An effector cytokine such as IFN-
γ could synergize the existing anti-CT activity of TNF-α for better
protection (28). However, our finding that CD4+ T cells which
co-produced IFN-γ with either TNF-α or IL-2 (based on dual
gating) were not associated with protection against reinfection
seemed to suggest that a CD4+IFN-γ T cell response is sufficient
for immune protection against CT reinfection; this has also been
described for infection from another Gram-negative bacteria,
Salmonella typhi (29). Our results are also consistent with our
previous findings that CT-antigen specific responses are quite
heterogeneous (18). We found differential cytokine responses
by antigen-specific T cells at follow-up, with the CD4+IFN-γ
response mainly elicited by CT Pgp3 and EB. Our findings are
relevant from a vaccine development perspective, as our results
suggest that more than one CT antigen may be required as
vaccine candidate for eliciting an effective immune response
against CT.
It has been hypothesized that early treatment of CT infection
in humans could hinder the development of protective immunity
in some individuals, a concept known as “arrested immunity”
(6, 9). In our study, we found that at follow-up after CT-
infected women were treated, there was a higher percentage
of women who had a CD4+IFN-γ response detected and the
magnitude of the response was stronger than the frequency and
magnitude of these responses at the treatment visit, irrespective
of their reinfection status. This suggests that in our study
population, antibiotic treatment did not completely prevent
the development of some degree of adaptive immunity with a
CD4+IFN-γ response that might aid in more rapidly clearing
infection in those who have reinfection. However, we were
limited in not knowing the duration of CT infection prior to
treatment.
Our study provides clear evidence in humans that a
CD4+IFN-γ response may be an immune correlate of protection
against CT reinfection and adds substantial evidence to existing
knowledge of the human immune responses in CT-infection. We
found that women who had a CD4+IFN-γ response detected
at follow-up were significantly less likely to have reinfection,
though the protection might not be long lasting, as possibly
suggested by our analyses of CD4+IFN-γ response stratified by
3-month vs. 6-month follow-up visit. Further analysis of the
CD4+IFN-γ response revealed that the responses against CT-
MOMP peptides were driving the association of a CD4+IFN-γ
response with protection against reinfection, implicating an
existence of differential immune dominance among women with
and without CT reinfection. Our analysis also revealed that
among those with a CD4+IFN-γ response detected, there was no
association between the magnitude of the CD4+IFN-γ response
and reinfection status, suggesting it is not the magnitude of
the CD4+IFN-γ response, rather the timing of the response
that influences reinfection risk. From a clinical perspective,
while a CD4+IFN-γ response appears to provide protection
against CT reinfection, we were unable to determine whether
some individuals had complete or partial immunity, the latter
which would likely manifest as a reinfection that is more
short-lived due to more rapid and effective immune-mediated
clearance. Additional insights into the degree of protective
immunity would require a study with more frequent CT
testing.
One of the limitations of our study was that our study
population was primarily comprised of African-American
women, and it is unclear if our findings can be extrapolated
to women of other race/ethnicities or to men. Our study
focused on cytokines associated with Th1 responses (against
3 CT antigens) due to the animal model data highlighting
the essential role of Th1 in protective immunity (13, 14, 30–
32); however, we did not investigate the contribution of Th2
responses in CT immunity, which may be important since a
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FIGURE 8 | Women presenting for follow-up after chlamydia treatment predominantly had a dual cytokine-producing CD4+ T cell response detected: Percentage of
women with CD4+ dual TNF-α IFN-γ responses and IFN-γ IL-2 responses detected after their PBMCs were stimulated with any of the three Chlamydia trachomatis
(CT) antigens among those with a positive CD4+ IFN-γ response. (A) Bar graph showing the difference in the percentage of women with CT infection at enrollment
who had a CD4+ dual cytokine response detected between the two visits: treatment (Tx) visit (white bars) and follow-up (FU) visit (black bars). A significantly higher
proportion of women at the FU visit had a CD4+ dual cytokine response detected compared to those at the Tx visit (P < 0.001). (B) Bar graph depicting the difference
in the percentage of women with CD4+ dual TNF-α +FN-γ responses and IFN-γ+IL-2 responses detected (determined using dual gating) from the reinfection (R)
(white bars) vs. the no reinfection (NR) (black bars) groups, after their PBMCs were stimulated with any of the three CT antigens. There was no significant difference in
the frequency of these dual CD4+ cytokine responses between women from the R and NR groups. Standard error of mean (SEM) is shown on the bars. An extension
of McNemar’s chi-square test was used to compare R vs. NR matched groups. P < 0.05 was considered statistically significant. ***P < 0.001, **P < 0.005, and *P <
0.05.
previous publication demonstrated that robust Th2 responses
have been detected in some CT-infected women (26). We did
not have mucosal mononuclear cells (MNCs) for evaluating
these same immune responses by ICS, so it is unknown if
our findings based on PBMC responses will translate to the
immune responses seen at the mucosal site. It is possible that
at the treatment visit, there were a significant proportion of
IFN-γ-producing CD4+ T cells residing in the mucosa and thus
were not measured in our PBMC studies. We realize that the
immune responses against CT could be not only temporal in
nature, but could also vary between the peripheral blood and
the mucosa, as the gene expression of CT is developmentally
regulated and thus different immune responses could be directed
against different proteins expressed. Thus, the same antigens
may or may not mount similar responses at the mucosa
as seen in periphery, and there could be different immune
dominant epitopes. Although a higher proportion of women in
the reinfection group reported having unprotected sex between
the treatment and follow-up visits, the immunological relevance
of this finding is not known. It could be possible that some
women who had more unprotected sex were more frequently
exposed to CT in a short period, which could influence the
type or magnitude of their immune responses; however, with
CT testing limited to the follow-up visit, our study was not
designed to identify frequency of CT exposures. While we
also found a significant increased magnitude of the IFN-γ-
producing CD4+ T cells at the follow-up visit, without memory
markers we cannot determine if they are expanded memory
cells (effector memory) left after primary infection (which
is highly likely) or they were cells recruited back from the
mucosa after primary infection is cleared (central memory).
While we found a trend toward lower reinfection frequency
in those with prior chlamydia, our prior chlamydia variable
was limited in that it was based on participant self-report
and medical record review of chlamydia test results from
only the study clinic. Therefore, there may have been some
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misclassification of prior chlamydia status, which was most likely
an underestimate of the proportion of subjects with prior CT
infection.
In future studies, we plan to decipher the role of Th1
responses at the primary site of infection (mucosal site) and to
validate that CT-specific IFN-γ-producing CD4+ T cells traffic
to mucosa and are directly involved in providing protection.
We will also evaluate the immune dominance of various CT-
antigens to identify specific epitopes that may be the primary
target of the immune mediated response against CT. We will also
determine whether the IFN-γ-producing CD4+ T cells at follow-
up are of memory origin; in general, memory T cells mount a
stronger and more robust T cell response upon re-challenge with
a pathogen (33).We also plan to investigate if onememory subset
is dominant over other in women without reinfection vs. with
reinfection.
In conclusion, women with CT infection had an
adaptive immune response to CT detected after therapy
that was more CD4+IFN-γ centric compared to the TNF-
α dominant response prior to treatment. A CD4+IFN-γ
response was more often detected at follow-up in women
without reinfection vs. those with reinfection, suggesting
CD4+IFN-γ may provide some degree of protective immunity
against CT reinfection and could serve as a correlate of
protection, which would be important in future research
studies evaluating CT antigens for CT vaccine development
or evaluating CT screening strategies based on immune
correlates.
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